- Home
- UPXI vs PHIO Comparison
UPXI vs PHIO Comparison
Compare UPXI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- PHIO
- Stock Information
- Founded
- UPXI 2018
- PHIO 2011
- Country
- UPXI United States
- PHIO United States
- Employees
- UPXI N/A
- PHIO N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- PHIO Health Care
- Exchange
- UPXI Nasdaq
- PHIO Nasdaq
- Market Cap
- UPXI 3.9M
- PHIO 3.4M
- IPO Year
- UPXI 2021
- PHIO N/A
- Fundamental
- Price
- UPXI $3.46
- PHIO $2.77
- Analyst Decision
- UPXI Hold
- PHIO Strong Buy
- Analyst Count
- UPXI 1
- PHIO 1
- Target Price
- UPXI $25.00
- PHIO $36.00
- AVG Volume (30 Days)
- UPXI 50.7K
- PHIO 18.5M
- Earning Date
- UPXI 02-12-2025
- PHIO 11-14-2024
- Dividend Yield
- UPXI N/A
- PHIO N/A
- EPS Growth
- UPXI N/A
- PHIO N/A
- EPS
- UPXI N/A
- PHIO N/A
- Revenue
- UPXI $22,082,477.00
- PHIO N/A
- Revenue This Year
- UPXI $299.03
- PHIO N/A
- Revenue Next Year
- UPXI N/A
- PHIO N/A
- P/E Ratio
- UPXI N/A
- PHIO N/A
- Revenue Growth
- UPXI N/A
- PHIO N/A
- 52 Week Low
- UPXI $2.17
- PHIO $1.53
- 52 Week High
- UPXI $33.00
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- UPXI 39.66
- PHIO 50.99
- Support Level
- UPXI $3.31
- PHIO $2.41
- Resistance Level
- UPXI $4.10
- PHIO $4.53
- Average True Range (ATR)
- UPXI 0.41
- PHIO 0.83
- MACD
- UPXI -0.04
- PHIO 0.12
- Stochastic Oscillator
- UPXI 9.38
- PHIO 14.18
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.